laboratory for invasive hemodynamic exercise stress testing were enrolled. Written informed consent was provided by all subjects before participation in study-related procedures. The trial was approved by the Mayo Clinic Institutional Review Board and was registered (NCT02262078).
Study Population
HFpEF was defined by clinical symptoms of chronic HF (dyspnea and fatigue), normal EF (≥50%), and elevated left heart filling pressures (pulmonary capillary wedge pressure [PCWP] ) at rest (>15 mm Hg) and with exercise (≥25 mm Hg). [2] [3] [4] [5] 8 Exclusion criteria included significant valvular heart disease (>mild stenosis, >moderate regurgitation), cor pulmonale, significant pulmonary disease, congenital heart disease, glucose 6-phosphate dehydrogenase deficiency, left to right shunt, unstable coronary artery disease, myocardial infarction within 60 days, hypertrophic or infiltrative cardiomyopathy, primary renal or hepatic disease, high output HF, or constrictive pericarditis. Patients receiving chronic organic nitrates or phosphodiesterase 5 inhibitors were also excluded.
Study Protocol
Subjects were studied on their chronic medications in the postabsorptive state and supine position. Cardiac catheterization was performed with simultaneous expired gas analysis at rest and during supine exercise at 20-Watt (W) workload for 5 minutes as previously described. 3, 5, 8 After the first exercise phase (before any drug administration) and after return to steady-state baseline hemodynamic values, subjects were randomized in a 1:1 fashion using a simple computer-generated randomization program to nebulization of either placebo (inhaled normal saline) or inhaled nebulized sodium nitrite (90 mg; Mast Therapeutics) administered via the Solo-Idehaler device (Aerogen Galway, Ireland/DTF Saint-Etienne, France).
For systemically acting drugs, a high percentage of particles need to reach the alveoli deep within the periphery of the lung, allowing for fast and efficient absorption via gas exchange. The nebulizer device used in this trial achieves robust alveolar delivery of study drug as it aerosolizes to small particles (≤5 μm) that behave like gas molecules reaching the terminal alveoli, with much higher efficiency than pneumatic nebulizers that aerosolize to larger particles (5-10 μm) that are deposited by inertial impact primarily to the throat and upper airways. [9] [10] [11] The nitrite/placebo nebulizations were identical in appearance and were prepared by the research pharmacy, ensuring double-blinding so both the patient and investigator were unaware of nebulizer content. After 5 minutes, hemodynamic measurements were repeated at rest, followed by repeat supine exercise at 20 W for 5 minutes, identical to the first phase of the study. Hemodynamic, arterial, and venous blood samples and expired gas data were acquired during each stage of the protocol.
Catheterization Protocol
Right heart catheterization was performed through a 9-French sheath via the internal jugular vein. Transducers were zeroed at midaxilla. Pressures in the right atrium (RAP), pulmonary artery (PA), and pulmonary capillary (PCWP) were measured at end expiration (mean of ≥3 beats) using 2-French high-fidelity micromanometer-tipped catheters (Millar Instruments, Houston, TX) advanced through the lumen of a 7-French fluid-filled catheter (Arrow) as previously described. 3, 5, 8 Mean RAP and PCWP were taken at mid A wave. PCWP position was verified by typical waveforms, appearance on fluoroscopy, and direct oximetry (saturation≥94%). Continuously recorded pressure tracings were digitized (240 Hz) and analyzed offline.
Arterial blood pressure (BP) was measured continuously through a 4-to 6-French radial arterial cannula. Oxygen consumption (Vo 2 ) was measured from expired gas analysis (MedGraphics, St Paul, MN) taken as the average from the 60 seconds preceding arterial and mixed venous blood sampling. Arterial-venous O 2 content difference (Cao 2 −CvO 2 ) was measured directly as the difference between systemic arterial and PA O 2 content. Cardiac output (CO) was determined by the direct Fick method (=Vo 2 /[Cao 2 −CvO 2 ]). Stroke volume (SV) was determined from the quotient of CO and heart rate. CO and SV were indexed to body surface area. Pulmonary vascular resistance (PVR=[mean PA−PCWP]/CO), PA compliance (PAC=SV/[PA pulse pressure]), and systemic vascular resistance ([mean BP−RAP]×80/CO) were calculated using standard formulas. 8 
Blood Samples
Central venous and arterial blood samples were obtained during each stage to measure methemoglobin level and blood gases. Plasma nitrite concentrations were assessed using a liquid chromatography fluorometric assay (BASi, West Lafayette, IN) as previously described. 
Study End Points
The primary end point of the trial was the PCWP during exercise. Secondary end points included changes in resting PCWP as well as rest and exercise changes in RAP, PA pressure, PVR, PAC, systemic BP, heart rate, SV, CO, Vo 2 , and Cao 2 −CvO 2 . Methemoglobin level (%) was assessed as a safety end point.
Statistical Analysis
Results are reported as mean (SD), median (IQR), or number (%). Between-group differences at individual time points were tested using Student's t test, Wilcoxon rank-sum test, or Fisher exact test. Withingroup differences are assessed by paired t test. The effect of nitrite on the primary end point of exercise PCWP was assessed by analysis of covariance, using the initial exercise PCWP measured before study drug as the covariate. Between-group differences in rest or exercise hemodynamic responses were compared by unpaired t test after accounting for respective prestudy drug values. Linear regression was performed to compare hemodynamic responses to exercise before and after study drug, with variables log-transformed as necessary for analysis. All tests were 2-sided, with a P value <0.05 considered significant. Analyses were performed using JMP 10.0.0 (SAS Institute, Cary, NC).
Results
Of the 70 screened patients, 32 were excluded based on entry criteria (13 lung disease, 9 valvular disease, 5 on organic nitrates, 3 advanced liver/kidney disease, and 2 coronary disease), and 12 subjects were excluded because they did not meet the hemodynamic criteria for HFpEF (n=10) or because systemic arterial pressures were too low (n=2). A total of 26 subjects met all entry criteria and were enrolled in the trial between December 2014 and December 2015. Participants were older aged, obese, and displayed typical comorbidities associated with HFpEF, including hypertension, diabetes mellitus, and coronary artery disease (Table 1) . On average, subjects displayed normal LV chamber size and mass, mild LV diastolic dysfunction, and elevated NTproBNP (N-terminal pro brain natriuretic peptide) levels, with no differences between subjects randomized to placebo or nitrite.
Rest and Exercise Hemodynamics Before Study Drug
At rest, HFpEF subjects were hypertensive, with moderate to severely elevated right and left heart filling pressures, mild to moderate PH, elevated PVR, low PA compliance, and normal Table 2 ). Right and left heart filling pressures increased markedly during exercise (mean RA and PCWP, 23 and 34 mm Hg, respectively), with secondary elevation in PA pressures. Twenty-two subjects (85%) had both elevated resting and exercise PCWP. Four subjects (15%; 3 nitrite and 1 placebo) had normal resting PCWP but elevated exercise PCWP. Ventilatory efficiency (V E /V Co2 slope) was elevated in HFpEF subjects (38±6), in keeping with advanced disease. Subjects randomized to placebo tended to display higher PA pressures and PVR at rest and exercise as compared with subjects randomized to nitrite, along with significantly lower PA compliance at rest and on exercise and higher PVR on exercise (Table 2) . Resting Vo 2 was higher in subjects randomized to nitrite, but this was no longer significant after adjusting for body mass (P=0.5).
Effects of Nitrite at Rest
There was no effect of inhaled nitrite on heart rate or BP at rest (Table 3) . However, as compared with placebo, inhaled nitrite reduced RAP, PCWP, and PA pressures while improving PA compliance (Table 3 and Figure 1 ). Nitrite had no effect on resting pulmonary or systemic vascular resistance, Vo 2 , cardiac index (CI), Cao 2 −CvO 2 , or SV index compared with placebo.
Effects of Nitrite on Exercise Hemodynamics
The primary end point of exercise PCWP was significantly improved with nitrite compared with placebo (adjusted mean 25±5 versus 31±6 mm Hg, analysis of covariance P=0.022; Table 4 and Figure 2 ). The reduction in exercise PCWP with nitrite was >2-fold greater than the reduction observed in resting PCWP post nitrite.
Nitrite had no effect on exercise heart rate or systolic BP, but it tended to reduce mean BP during exercise more than placebo (P=0.07; Table 4 ). Nitrite decreased exercise RA and PA mean pressures compared with placebo. Although there was no effect of nitrite on exercise PVR or PA compliance, subjects with higher PVR displayed greater PVR reductions with nitrite measured at baseline (r 2 =0.56; P=0.005) and during exercise (r 2 =0.68; P<0.001). This relationship was not observed in the placebo group. V E /V Co2 slope tended to be lower after nitrite as compared with placebo (+1±4 versus +3±3 compared with prestudy drug; P=0.26). Nitrite had no effect on exercise systemic vascular resistance, Vo 2 , Cao 2 −CvO 2 , CI, or SV index. 
Pharmacokinetics
Plasma nitrite levels were undetectable at baseline and with exercise before study drug in all subjects. Nitrite (NO 2 ) levels increased to 11.1±4.9 μmol/L before exercise in subjects receiving active drug (P<0.0001 versus baseline). After the 5-minute exercise period, NO 2 levels decreased to 9.1±3.9 μmol/L (P=0.002 compared with pre-exercise values). The calculated half-life of nitrite in this study was 0.72±0.74 hours. Higher NO 2 levels tended to be associated with greater reductions in exercise PCWP (r=−0.44; P=0.13) and PA systolic pressure (r=−0.46; P=0.11).
Discussion
There are 2 important new findings presented. We show for the first time that nebulized inhaled inorganic sodium nitrite favorably reduces PCWP, an important, clinically relevant end point, both at rest and, particularly, during exercise when symptoms develop in people with HFpEF. Second, we show for the first time in a placebo-controlled trial that a nebulized drug formulation can be effectively delivered to achieve pharmacokinetic and pharmacodynamic effects that are similar to intravenous administration in subjects with HFpEF. The beneficial acute hemodynamic effects of inhaled nitrite provide strong rationale to conduct trials testing inhaled nitrite as a chronic therapy in HF. The proof of efficacy using this novel micronebulized drug delivery system paves the way for testing other parenterally administered drugs that may be efficacious for people with acute or chronic HF. The pathophysiology of HFpEF is complex, being related to left and right ventricular dysfunction, vascular limitations, and impairments in the periphery. 1, 2, 12 Despite this complexity, elevation in cardiac filling pressures at rest and with exercise is a nearly universal finding. [3] [4] [5] Elevated LV filling pressures drive symptoms of dyspnea, they contribute to PH and development of right ventricular dysfunction, 13 and they are associated with increased risk of death, even when observed only during exercise.
14 Many patients with HFpEF display high filling pressures during exercise, with normal PCWP at rest, [3] [4] [5] and treatments that reduce filling pressures relatively more during exercise might be more effective and better tolerated than standard pharmacological approaches like diuretics.
Limitations in NO availability are believed to play a key role in driving the elevations in filling pressures and PH in HFpEF, 1, 6 and agents targeting the NO/cGMP pathway represent an area of intense interest. 15 One of the oldest approaches to target this pathway is using direct NO donors, such as the organic nitrates. This served as the guiding hypothesis for the NEAT-HFpEF trial (Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction), where the organic nitrate isosorbide mononitrate was found to decrease rather than increase chronic activity levels in HFpEF, as had been hypothesized. 16 Although this result may seem to speak against the importance of NO deficiency in HFpEF, there are number of important caveats. Organic nitrates tonically release NO, so there is not targeted delivery at the time of greatest need (as with exercise). This tonic release may cause venodilation and secondary plasma volume expansion that counteracts any benefits on PCWP reduction (pseudo-tolerance). 17 Pharmacological tolerance is common with organic nitrates, and organic nitrates are clearly associated with the development of endothelial dysfunction, 18 which is known to be present in HFpEF and associated with greater symptom severity, functional disability, and worse outcomes. 19, 20 In contrast to the organic nitrates, there is no tolerance and no development of endothelial dysfunction with inorganic nitrite. 7, 21 Nitrite and its precursor nitrate were previously considered to be inert byproducts of NO metabolism, but studies over the past decade have shown that nitrite can be reduced back to NO in vivo. This reaction is facilitated in the setting of venous or tissue hypoxia and acidosis, conditions which accompany exercise. As such, nitrite provides a hypoxia-sensitive NO source that is preferentially active at the time of greatest need, allowing for more targeted NO delivery. Nitrite can be administered directly or it may be derived from orally administered nitrate that acts as a prodrug that must undergo reduction by commensal bacteria to nitrite in the mouth before swallowing.
Preclinical and clinical studies have shown benefits from inorganic nitrite and nitrate in HFpEF. 7, 8, [21] [22] [23] [24] [25] In human HFpEF, oral nitrate (delivered as beetroot juice) improves exercise capacity, vasodilation, and CO reserve when given either as a single dose or as repeated doses over 1 week. 22, 23 Intravenous nitrite reduces PCWP at rest and during exercise while also improving PA pressures and CO reserve in HFpEF. 8 Similar benefits have also been reported with intravenous nitrite in patients with HFrEF (heart failure with reduced ejection fraction). 26 An important consideration when comparing nitrate and nitrite formulations is that plasma NO 2 levels with nitrate are an order of magnitude lower than intravenously administered nitrite, 8, 27 and it is not clear that central hemodynamic benefits would be observed with oral nitrate formulations, particularly given the observed relationship between NO 2 levels and PCWP reduction.
Inhaled nitrite has been developed as an alternative drug delivery route with the potential to enable chronic use, circumventing the requirement for intravenous administration. 7, 9 The current data show that inhaled nitrite achieves similar plasma NO 2 levels as the intravenous formulation (≈10-12 μmol/L), and like parenteral nitrite, 8 nebulized inhaled nitrite achieves similar pharmacodynamic effects, with reduction in biventricular filling pressures at rest and during exercise, along with decreases in PA pressures. In contrast to intravenous nitrite, 8 inhaled nitrite did not increase SV, stroke work, or CO reserves in the current study. The reasons for this differential effect remain unclear, but may relate to lesser systemic vasodilation because exercise systemic vascular resistance was not affected by inhaled nitrite but was reduced with intravenous nitrite. The half-life of inhaled nitrite in this trial was 43 minutes, which is similar to what has been reported in healthy volunteers. 9 Currently, this requires administration every 6 hours during the daytime. However, there is reason to think that the salutary effects of nitrite may persist even as plasma levels return to baseline because there are sustained reductions in PA pressure in both humans and mice at trough concentrations. 28, 29 These sustained effects may be related to longer-lived species, such as nitrosothiols and NO-hemoglobin adducts. The ease of use and rapid onset of action with inhaled nitrite suggests that it might be used chronically in a scheduled fashion 3× daily, before planned physical activity, or even on an as-needed basis for relief of dyspnea. As such, the efficacy of chronic inhaled nitrite in HFpEF is currently being tested in 2 clinical trials sponsored by the NHLBI (NCT02742129 and NCT02713126).
Nitrite has also been suggested as a treatment for pulmonary arterial hypertension. 7, 25, [28] [29] [30] In the current study, pulmonary arterial compliance was improved with nitrite at rest, consistent with a pulmonary vascular effect. Although PVR was not improved overall, participants with the most intense PA vasoconstriction (highest PVR) did display greater pulmonary vasodilation with nitrite-an effect that was not observed in subjects receiving placebo. This observation raises the hypothesis that nitrite might be more effective as a pulmonary vasodilator in patients with more advanced precapillary causes of PH, whether it is secondary to chronic HF or primary pulmonary arterial diseases. This question merits further study.
The adult lung contains 300 million alveoli, which serve as the primary sites for gas exchange between the blood and external environment. The lung alveolar-capillary interface, thus, represents one of the fastest and most efficient sites for absorption of systemically active drugs. 11 However, to date, this potential route of administration has been overlooked in HF patients. To achieve systemically relevant biological effects, a high percentage of drug particles need to reach the alveoli. 10, 11 The efficiency and location of the deposition depends largely on the size of the particles and the velocity of inspiratory flow. Conventional pneumatically powered nebulizers do not produce small enough particle sizes to achieve alveolar deliver, with an overall efficiency of <20%. In contrast, the efficiency of the device used in the current trial is much higher (≈75%), 9 and as shown from the pharmacokinetic data, this enables drug absorption to systemic levels seen with parenteral administration, with very rapid onset of action. These data suggest that other parenterally active therapies in HF might be administered using this approach, which could greatly expand the armamentarium of medications available for chronic use. These data also suggest one way of speeding the process of drug development for new intravenously available compounds targeting novel pathways in HF.
Limitations
Patients with conditions that might independently cause symptoms were excluded, including patients with severe valvular or coronary heart disease and those with advanced lung, liver, or kidney disease. Thus, we cannot determine whether the current results would apply to HFpEF patients with those comorbidities. Hemodynamic effects of nitrite were assessed in the supine position in this trial. Although filling pressures are lower when upright as compared with supine, prior studies have shown that the changes in pressures with exercise are similar regardless of body position, 31 suggesting that the beneficial effects of nitrite may be similar, though we cannot make any conclusions about upright hemodynamics from these data. Cardiac volumes were not assessed during the study, limiting the ability to determine potential effects of nitrite on ventricular diastolic properties. Exercise was performed at low workload (20 W) rather than peak. This was done to ensure feasibility and minimize any carryover effect of the initial (prestudy drug) exercise test to the second exercise test after study drug. Thus, we cannot make any conclusions about the effect of inhaled nitrite on maximal exercise capacity. However, this level of activity is highly relevant to patients' activities of daily living. Chronic effects of inhaled nitrite cannot be addressed from this acute study but are the subject of investigation of other trials that are currently underway.
Conclusion
Nebulized inhaled inorganic nitrite favorably attenuates hemodynamic derangements that are present at rest and during exercise in HFpEF. Further study is indicated to determine whether chronic inhaled nitrite administration can improve clinical status in people with HFpEF and other forms of HF and PH and whether other parenterally administered medicines in HF might also be delivered by inhalation to improve clinical status.
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What Is Known?
• Impaired nitric oxide bioavailability is associated with hemodynamic abnormalities in patients with heart failure with preserved ejection fraction (HFpEF) that drives symptoms and contributes to increased morbidity and mortality.
• Parenterally administered inorganic nitrite, which leads to production of nitric oxide independent of the traditional nitric oxide synthase pathway, has been shown to improve rest and exercise hemodynamics in patients with HFpEF.
• A disadvantage of inorganic nitrite use is the requirement for intravenous administration.
What New Information Does This Article Contribute?
• Inhaled sodium nitrite, delivered via a high efficiency micronebulizer device, reduces biventricular filling pressures both at rest and during exercise as compared with placebo in patients with HFpEF.
• Pharmacokinetic and pharmacodynamic effects with inhaled nebulized nitrite were similar to what has been reported with intravenous administration, suggesting that inhaled nitrite may be effective as a chronic therapy.
HFpEF is a common cardiovascular problem without a proven effective treatment. Intravenous sodium nitrite augments nitric oxide signaling and has been shown to improve hemodynamic derangements that are associated with symptoms in patients with HFpEF. Currently, use of this compound is limited by the need for parenteral administration. We performed a randomized, doubleblind, placebo-controlled trial showing that inhaled sodium nitrite significantly attenuates hemodynamic derangements in patients with HFpEF, both at rest and during exercise. This is the first trial to show that a parenterally active drug can be delivered via an inhaled nebulized route in patients with HFpEF. Inhaled nebulized nitrite shows pharmacokinetics and pharmacodynamic effects similar to the parenteral form. These data have 2 major implications: (1) that inhaled nitrite may be effective as a chronic therapy for HFpEF and (2) they open the door for testing inhaled forms of other intravenous drugs to target the pathogenic pathways in heart failure and other cardiovascular diseases.
